News | May 21, 2026
Eris Lifesciences reports Q4 FY26 revenue of Rs. 757 crore; PAT jumps 173%
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Next-generation berberine formulation developed with BioSOLVE Technology targets metabolic health, blood sugar balance, and weight management
Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care
Complex tumour removed in a young patient without major pancreatic loss, reducing risk of lifelong diabetes
The standout story remains Wegovy, particularly its new oral formulation
New policy aims to standardise screening, diagnosis and lifelong care for children with diabetes across India’s public health system
The Danish biotech company confirmed the global study will begin in the second half of 2026
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Searches for diabetes, heart conditions, and metabolism-related risks are rising sharply, with Tier 2 cities outpacing metros in specialist consultations
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
